April 28, 2020 / 10:59 AM / a month ago

Pfizer profit down 12% as sales of off-patent drugs fall

April 28 (Reuters) - Pfizer Inc reported a 12.4% drop in first-quarter profit on Tuesday, partly hurt by a drop in sales its off-patent pain treatment Lyrica.

Net income attributable to shareholders fell to $3.40 billion, or 61 cents per share, in the quarter, from $3.88 billion, or 68 cents per share, a year earlier.

Revenue at the company, which is set to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV, fell 8.3% to $12.03 billion. (Reporting by Saumya Sibi Joseph and Vishwadha Chander in Bengaluru; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below